These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 33932471)

  • 1. Platinum-based chemotherapy and bevacizumab instigate the destruction of human ovarian cancers via different signaling pathways.
    Kingnate C; Charoenkwan K; Kumfu S; Apaijai N; Jaiwongkam T; Khunamornpong S; Chattipakorn N; Chattipakorn SC
    Biochem Pharmacol; 2021 Jun; 188():114587. PubMed ID: 33932471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Adding Bevacizumab to Paclitaxel + Carboplatin for Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Propensity Score Matching Analysis.
    Hirasawa T; Machida H; Iida T; Ikeda M; Shida M; Mikami M
    Tokai J Exp Clin Med; 2018 Sep; 43(3):85-89. PubMed ID: 30191541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
    Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
    Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
    Abe M; Shoji T; Chiba Y; Takatori E; Kaido Y; Nagasawa T; Kagabu M; Takahashi F; Aida T; Baba T
    Anticancer Res; 2023 Mar; 43(3):1265-1272. PubMed ID: 36854492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effect of dose-dense paclitaxel plus carboplatin with or without bevacizumab for Japanese patients with epithelial ovarian cancer.
    Kochi Y; Hosoya S; Yanaihara N; Nagata C; Honda R; Shimazaki M; Yokosu K; Kuroda T; Saito M; Tanabe H; Yamada K; Takano H; Okamoto A
    Int J Clin Oncol; 2024 Sep; 29(9):1364-1379. PubMed ID: 38865025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer.
    Zhang L; Zhou Q
    Eur J Pharmacol; 2018 Oct; 837():64-71. PubMed ID: 30059681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
    Backes FJ; Richardson DL; McCann GA; Smith B; Salani R; Eisenhauer EL; Fowler JM; Copeland LJ; Cohn DE; O'Malley DM
    Int J Gynecol Cancer; 2013 Jun; 23(5):833-8. PubMed ID: 23640292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab, Carboplatin and Paclitaxel Combination Treatment in Advanced Stage Ovarian Cancer: The First Experience in Thammasat University Hospital, Thailand: A Case Report.
    Suwannarurk K; Thaweekul Y; Mairaing K; Poomtavorn Y; Tangtiang K; Piyawang W; Bhamarapravatana K
    J Med Assoc Thai; 2015 Apr; 98 Suppl 3():S121-5. PubMed ID: 26387399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
    Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
    Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
    Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
    J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Bevacizumab Combined with Albumin-Bound Paclitaxel in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer.
    Liu B; An R; Yu J
    J BUON; 2019; 24(6):2303-2309. PubMed ID: 31983098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors.
    Hyman DM; Rizvi N; Natale R; Armstrong DK; Birrer M; Recht L; Dotan E; Makker V; Kaley T; Kuruvilla D; Gribbin M; McDevitt J; Lai DW; Dar M
    Clin Cancer Res; 2018 Jun; 24(12):2749-2757. PubMed ID: 29559563
    [No Abstract]   [Full Text] [Related]  

  • 14. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
    Chan JK; Brady MF; Penson RT; Huang H; Birrer MJ; Walker JL; DiSilvestro PA; Rubin SC; Martin LP; Davidson SA; Huh WK; O'Malley DM; Boente MP; Michael H; Monk BJ
    N Engl J Med; 2016 Feb; 374(8):738-48. PubMed ID: 26933849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.
    Petrillo M; Amadio G; Salutari V; Paris I; Di Stefano MG; Ferandina G; Scambia G; Fagotti A
    Gynecol Oncol; 2016 Aug; 142(2):231-6. PubMed ID: 27215633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
    Ricci F; Guffanti F; Damia G; Broggini M
    Mol Cancer; 2017 May; 16(1):97. PubMed ID: 28558767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report.
    Tarumi Y; Mori T; Matsushima H; Kokabu T; Tsuchiya H; Kitawaki J
    J Obstet Gynaecol Res; 2018 Feb; 44(2):347-351. PubMed ID: 29121427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
    Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
    Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose (7.5 mg/kg) bevacizumab may be a viable option in recurrent ovarian cancer: A retrospective study.
    Demirkiran A; Eryilmaz MK; Karaagac M; Araz M; Korkmaz M; Koçak MZ; Artac M
    J Cancer Res Ther; 2023; 19(3):595-600. PubMed ID: 37470581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.